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A B S T R A C T
Background
Naturally acquired malaria immunity has many determinants and, in the absence of
immunological markers of protection, studies assessing malaria incidence through clinical
endpoints remain an approach to defining immunity acquisition. We investigated the role of
age in disease incidence and the effects of chemoprophylaxis on clinical immunity
development to Plasmodium falciparum during a randomised controlled trial.
Methods and Findings
A total of 415 Tanzanian infants were randomly assigned to receive weekly malaria
prophylaxis with Deltaprim (3.125 mg of pyrimethamine plus 25 mg of dapsone) or placebo
between the ages of 2 and 12 mo. Children were followed up until 4 y of age. Uncomplicated
febrile malaria, severe malaria, and anaemia morbidity were assessed through hospital-based
passive surveillance. Compared with the group of control participants, there was a marked
reduction in the incidence of clinical malaria, severe malaria, and anaemia in the group of
children who had received chemoprophylaxis during the first year of life. After discontinuing
the intervention, there was a significant increase in the incidence of clinical malaria for 2 y. The
cumulative rates of clinical malaria, by age 4 y, were slightly higher in the group of children
who had previously received chemoprophylaxis: 3.22 episodes versus 3.02 episodes in the
group of control participants; rate difference 0.20 (95% confidence interval [CI]:0.21 to 0.59).
By age 4 y, the cumulative rates of severe malaria, however, were slightly lower in
chemosuppressed children (0.47 versus 0.59) (rate difference0.12 [95% CI:0.27 to 0.03]). The
number of episodes of anaemia was also slightly lower in chemosuppressed children by age 4y:
0.93 episodes (95% CI: 0.79 to 0.97) versus 1.12 episodes in the group of control participants
(95% CI: 0.97 to 1.28) (rate difference 0.19 [95% CI: 0.40 to 0.01]), respectively.
Conclusions
Reducing exposure to P. falciparum antigens through chemoprophylaxis early in life can
delay immunity acquisition. Infants appear to acquire immunity faster than older children, but
have a higher risk of developing severe forms of malaria and anaemia. These findings provide
insight on the interplay between immunity and exposure-reduction interventions.
The Editors’ Summary of this article follows the references.
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Introduction
More than 100 y ago on the island of Java, Koch described
how the clinical and parasitological manifestations of malaria
decreased with age. He interpreted this as a function of
acquired resistance through exposure to the parasite [1].
However, despite a plethora of immunological investigations,
no surrogate marker of protective immunity has been
identiﬁed. A number of humoral and cellular immune
responses are known to be associated with reduced risk from
Plasmodium falciparum infection and disease [2], but none has
been shown to be causally related. Hence, studies assessing
malaria incidence through its different clinical endpoints
remain the best approach to determine the rate of acquiring
immunity.
The relationship between the risk of malaria—as a
surrogate of acquired immunity—and age is confounded by
the intensity of transmission, because people living in high-
transmission areas will tend to be exposed at younger ages.
Hence, it is unclear as to whether it is the frequency of
infection or age itself which is the prime determinant of the
clinical manifestations. To our knowledge, few studies have
had the opportunity to investigate the effect of age on the
development of malaria immunity. Perhaps the best informa-
tion comes from a descriptive study of parasitaemia in non-
immune migrants to malaria-endemic areas of Irian Jaya,
which suggested that adults acquired sterilizing immunity
more rapidly than children [3].
Information is also available on the age-related changes in
the manifestations of clinical malaria, principally cerebral
malaria and anaemia [4]. Malaria-associated anaemia is
typically described in younger children (i.e., ,2 y) [5].
Historically, older children are also suspected to have a
higher risk of cerebral malaria, but this age dependency is less
well deﬁned, owing partly to the difﬁculties in objectively
assessing the neurological status in infants.
In our opinion, the effects of a limited period of
suppression of malaria infection on the development of
naturally acquired immunity have been insufﬁciently ad-
dressed by current research. The most complete evaluation of
potential risks was carried out in the Gambia in the context
of a placebo-controlled intervention trial [6]. Maloprim was
administered for 5 y consecutively during the transmission
season to children aged between 6 mo and 5 y. The study
showed that there was a small, though not statistically
signiﬁcant, increase in the probability of dying during the
year after chemoprophylaxis was stopped, but that chemo-
prophylaxis was associated with an overall improvement of
survival [7].
A similar result was observed for malaria attacks. Malaria-
speciﬁc antibody levels at the end of chemoprophylaxis and 1
y later were lower, but the lymphoproliferative responses to
malaria antigens were increased in children who had received
chemoprophylaxis (chemosuppressed group) [8,9]. More
recently, a study in Tanzania gave infants malaria chemo-
prophylaxis with Deltaprim. The results of the intention-to-
treat analysis showed that malaria chemoprophylaxis had an
efﬁcacy of 60.5% and 57.3% in reducing the incidence of
clinical malaria and severe anaemia, respectively, up to the
age of 13 mo. However, after stopping chemoprophylaxis, the
risks of both outcomes increased in the previously chemo-
suppressed group until the age of 18 mo, by 1.8 and 2.2,
respectively [10].
Our study reports the effects of malaria chemoprophylaxis
given during the ﬁrst year of life on malaria, severe malaria,
severe anaemia, and general morbidity during 4 y of clinical
follow-up. Improved understanding of the development and
determinants of anti-malaria immunity and the ability to
cope with severe manifestations will not only help the
rational design of vaccines, but will provide information as
to the most appropriate use of malaria-control tools.
Methods
Study Area
The study was conducted between 1995 and 1999 in
Ifakara, a town in the Kilombero District of the Morogoro
region in Tanzania. The demographic and geographic
characteristics of the area have been described in detail
elsewhere [10]. At the beginning of the study, P. falciparum
malaria transmission in the area was highly endemic; the
average entomological inoculation rate (EIR) in a nearby
village was about 300 infective bites per person per year [11].
During the course of this study, the malaria epidemiology
changed [12], and an EIR of 29 (95% conﬁdence interval [CI]:
19 to 44) was documented in 2000 [13]. St. Francis Designated
District Hospital (SFDDH), a 370-bed facility, and its adjacent
maternal and child-health clinic serve the town. A number of
pharmacies and health dispensaries have also opened since
deregulation of the health sector in the late 1990s. Malaria
control during the study period relied on the prompt
treatment of presumptive episodes with chloroquine. How-
ever, the prevalence of parasite resistance to chloroquine was
very high (approximately 70% parasitological failure at day 7)
[14]. The use of mosquito nets increased in the area from
about 51% in 1996 to 71% in 2001. Malaria was responsible
for 37% of all paediatric admissions to SFDDH in 1995, with a
3% case-fatality rate. There was a marked age dependence of
malaria disease and death; 44% of cases and 54% of the
inpatient malaria deaths occurred in children aged less than 1
y [5]. Severe anaemia (packed cell volume [PCV] ,25%) was
also an important cause of hospital admission and death; 41%
of children aged less than 1 y were admitted with severe
anaemia and, of these, more than 53% received a blood
transfusion [5].
Study-Design Population
In January 1995, a four-arm randomised placebo-con-
trolled trial began assessing the efﬁcacy of malaria chemo-
prophylaxis with weekly Deltaprim (3.125 mg of
pyrimethamine plus 25 mg of dapsone) and/or iron supple-
mentation between 2 and 12 mo of age for the prevention of
malaria and anaemia in infants. Details of the study design
and results during the ﬁrst 18 mo of follow-up have been
described elsewhere [10]. Only infants whose mothers had
given written informed consent took part in the study.
Research and ethical clearance was granted by the Medical
Research Coordination Committee of the National Institute
for Medical Research through the Tanzanian Commission of
Science and Technology and the Hospital Clinic Ethics
Committee in Barcelona, Spain. The present analysis is based
on the incidence of overall and severe malaria morbidity, as
well as severe anaemia, detected through the hospital-based
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passive case-detection system during the 4-y period following
recruitment. In order to avoid any possible confounding
effect of the iron supplementation, the two cohorts of
children receiving iron are not included in this analysis.
The long-term effects and safety of iron supplementation are
presented elsewhere (Menendez et al., unpublished data).
Morbidity Surveillance
Since 1994, SFDDH and its adjacent maternal and child-
health clinic have used a round-the-clock, passive case-
detection surveillance system. Project ofﬁcers issued a
questionnaire, which recorded a patient’s main symptoms
and signs upon admission, and they also conducted basic
laboratory investigations for all children who were ill. A
unique identiﬁcation card given to all study participants
(children who had received chemoprophylaxis [chemosup-
pressed group] as well as control participants) at recruitment
allowed their identiﬁcation during all contact with the
project personnel. A system of bi-monthly demographic
surveillance provided information on vital events not
registered at the hospital. Malaria smears were prepared for
all inpatients and for out-patients when there was fever,
history of fever, or pallor.
Laboratory Methods
Thick blood ﬁlms were stained with Giemsa and read on a
light microscope following standard quality-control proce-
dures [15]. The PCVs were measured using a micro-centrifuge
and a Hawksley haematocrit reader (http://www.hawksley.co.
uk/).
Statistical Methods and Definitions
Clinical malaria was deﬁned as an episode of fever (axillary
temperature .37.5 8C) plus P. falciparum parasitaemia of any
density at any contact with the health services. Severe
anaemia was deﬁned as a PCV of less than 25% at any
contact with the health services. Severe malaria was deﬁned as
the presence of parasitaemia together with any of the
following risk factors: dehydration, respiratory distress,
impaired consciousness, and hypoglycaemia. These factors
were selected because they had been previously shown to be
independently associated with death for children in the study
setting [5]. In order to avoid double counting of episodes,
children who had been treated for clinical malaria, severe
malaria, or severe anaemia were considered not to be at risk
for a new episode during a 28-d period after beginning
treatment. For each outcome (clinical malaria, severe malaria,
and severe anaemia), a monthly incidence was calculated
using the number of episodes divided by the time during
which the patient had been at risk and expressed as episodes
per person-years at risk (PYAR) for the two groups.
The effect of chemoprophylaxis on the risk of clinical
malaria and anaemia changes with age, and is different before
and after the period of chemoprophylaxis. Thus, in order to
produce smooth estimates of the effect of chemoprophylaxis
with age, we modelled the incidence of clinical malaria, severe
anaemia, and other outcomes using Poisson regression
models of small time intervals, and imposing Bayesian
autoregressive constraints. This type of model allows the
effect of chemoprophylaxis to change with time but, for any
given time period, the effect should be similar to the effect in
the previous period of time. Details of the models are
presented in Protocol S1.
In order to compare the occurrence of malaria, anaemia,
or other outcomes, we calculated the cumulative rate (CR) as
the area under the curve for the estimated monthly incidence
in each treatment group. The CR at any given age could be
interpreted as the expected number of episodes that a child
experiences up to that age. Details of the CR estimation are
presented in Protocol S1. The graphs were produced using
Stata version 8.0 (Stata Corporation, http://www.stata.com/)
software. For the Bayesian models, we present the mean
posterior value and the 95% CIs. Bayesian models were ﬁtted
using WinBugs 1.4 [16] and the Bugs.R procedure [17].
Results
The trial proﬁle for the intervention and corresponding
cohort of control participants is shown in Figure 1. Of the
original 415 children, 256 (61.7%) completed the 4 y of
follow-up. Thirty-two children (7.7%) died, 121 (29.2%)
migrated or were lost to follow-up, and six (1.4%) refused
to continue in the study.
Risk of Clinical Malaria
Figures 2–4 present the relationship between the different
outcomes and age. The age-speciﬁc monthly incidence of
clinical malaria in the two cohorts is shown in Figure 2A. The
malaria risk in children receiving placebo declined slowly
during the ﬁrst 4 y of life, from 0.96 episodes/PYAR in
children aged between 2 and 12 mo of age to 0.72 episodes/
PYAR in children aged between 1 and 4 y (Table 1). The risk
of malaria during the ﬁrst year of life was dramatically
reduced to 0.31 episodes/PYAR by chemoprophylaxis,
although there was a clear tendency for the size of this effect
to decrease as the infants became older. Once prophylaxis
was stopped, chemosuppressed children had a signiﬁcantly
higher rate of clinical malaria compared with their contem-
porary control participants, and this higher rate lasted for at
least 18 mo (Figure 3A).
Figure 4A shows the CR for clinical malaria in the two
cohorts. The advantage gained by the group of children who
had received chemoprophylaxis during the ﬁrst year of life
Figure 1. Trial Profile
doi:10.1371/journal.pmed.0040242.g001
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was lost within the following 12 mo. At the end of the follow-
up period, the CR was slightly higher in the chemosuppressed
group versus the group of control participants; 3.22 episodes
versus 3.02 episodes, CR difference of 0.20 (95% CI:0.21 to
0.59).
Risk of Severe Malaria
Figure 2B shows the monthly incidence of severe malaria
between the two cohorts. Among children who were chemo-
suppressed during their ﬁrst year of life, the distribution of
severe malaria episodes is shifted to the right; by the age of 4
y, they experience an incidence rate of 0.32 episodes/PYAR.
Children in the placebo group (control participants) had an
average of 0.59 (95% CI: 0.48 to 0.71) episodes of severe
malaria (Table 1) by the age of 4 y. Figure 3B shows the
evolution of the relative rate of having a severe malaria
episode during the 4 y of follow-up. As with the pattern for
Figure 2. Incidence of Clinical Manifestations of Malaria by Group and Age
(A) Clinical malaria, (B) severe malaria, and (C) severe anaemia. Episodes per PYAR are shown.
doi:10.1371/journal.pmed.0040242.g002
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clinical malaria, the rebound in the risk of severe malaria
starts immediately after discontinuing prophylaxis, but in this
case is shorter, lasting for approximately 1 y. Thereafter,
there is a tendency for the risk of severe malaria to be lower
in the chemosuppressed group, but the difference is not
signiﬁcant. By the end of the follow-up period at the age of 4
y, the CR of severe malaria episodes was slightly lower in the
intervention cohort of children who had received chemo-
prophylaxis during the ﬁrst year (0.59 versus 0.47), with a rate
difference of 0.12 (95% CI: 0.27 to 0.03) (Figure 4B).
Risk of Severe Anaemia
Figure 2C shows the monthly incidence of severe anaemia.
On average, by the age of 4 y, children will have had 1.12 (95%
Figure 3. Relative Rates of Clinical Manifestations of Malaria by Age
(A) Clinical malaria, (B) severe malaria, and (C) severe anaemia. Relative-rate values higher than 1 indicate a higher incidence in the chemoprophylaxis
group, whereas relative-rate values lower than 1 indicate a higher incidence in the placebo group.
doi:10.1371/journal.pmed.0040242.g003
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CI: 0.97 to 1.28) episodes of anaemia with a PCV of ,25%;
nearly half these episodes are in children aged less than 1 y
(Table 1). This corresponds to an incidence rate of 0.77
episodes/PYAR.
Figure 3C compares the relative rate of developing
anaemia up to the age of 4 y in the two cohorts. During
prophylaxis, the anaemia rate was signiﬁcantly lower in the
chemosuppressed group, but there was a tendency for the
efﬁcacy of the intervention to decrease over time. Thereafter,
there was an increased risk of anaemia in the intervention
group that did not equalize until around 30–36 mo of age.
Figure 4C shows that the magnitude of the rebound for
anaemia is relatively small. By the age of 4 y, chemosup-
pressed children had experienced a marked reduction in the
risk of anaemia, and had a reduced CR (0.93 episodes [95%
CI: 0.79 to 0.97] versus 1.12 [95% CI: 0.97 to 1.28]),
corresponding to an overall difference of 0.19 (95% CI:
0.40 to 0.01).
Figure 4. CRs of Clinical Manifestations of Malaria by Group and Age
(A) Clinical malaria, (B) severe malaria, and (C) severe anaemia.
doi:10.1371/journal.pmed.0040242.g004
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Risk of Hospital Admissions
Children in the placebo group had, on average, 3.3 hospital
admissions during the ﬁrst 4 y of life (95% CI: 3.03 to 3.60),
compared to 3.1 admissions (95% CI: 2.83 to 3.37) for
children who had received chemoprophylaxis during the ﬁrst
year. The admission rate was highest in infants and decreased
sharply with age (incidence rate of 1.25 admissions/PYAR).
Discussion
This study investigated the development of clinical
immunity against malaria during the ﬁrst 4 y of life in two
contemporaneous cohorts of children experiencing P. falci-
parum infections at different ages. A major strength of this
study was that, although transmission intensity varied over
the course of follow-up, both cohorts were similarly exposed
to malaria. The incidence of clinical malaria in children
receiving placebo fell gradually during the ﬁrst 4 y of life,
reﬂecting the natural development of immunity to uncom-
plicated clinical disease. However, the documented rate of
immunity acquisition was slower than expected given the
moderate-to-high transmission rate that had been estimated
in the area. This may be partly explained by the fact that the
study population had prompt access to diagnosis and treat-
ment, which may delay the development of immunity [18,19].
Nonetheless, immunity development against severe malaria
and severe anaemia in the group of control participants was
faster, and was consistent with the long-standing view that a
relatively small number of infections are sufﬁcient to develop
reasonably solid protection against the more severe con-
sequences of P. falciparum infection [20].
Malaria chemoprophylaxis with Deltaprim in children aged
between 2 and 12 mo caused a signiﬁcant decrease in the risk
of febrile malaria, anaemia, hospital admission, severe
malaria, and all causes of hospital attendance during the ﬁrst
year of life. However, the reduction in these endpoints
decreased with increasing age, approaching zero towards the
end of the ﬁrst year of life. The cause of this trend is
unknown. Compliance did not decrease, and it is unlikely that
drug resistance would develop in such a short timeframe. It is
possible that the use of a standard recommended dose during
the prophylaxis period, which was unlinked to a dose per
weight of the child, resulted in sub-therapeutic drug concen-
trations in older children. A hypothetical reduction with age
in the synergy between declining maternally transferred
immunity and a moderately efﬁcacious drug may also
contribute to the loss of drug efﬁcacy during the ﬁrst months
of infancy. However, the loss in efﬁcacy was also apparent in
the latter months of infancy when transplacentally trans-
ferred antibodies are not expected to remain [21].
During the entire follow-up period, the difference in
deaths was not statistically signiﬁcant (19 versus 13 deaths, p¼
0.512). There was an increased number of deaths in the
chemosuppressed group (ten deaths versus three, p¼0.088) in
the 2–4 y age group. However, we were unable to obtain
information on the causes and circumstances of those deaths.
Given that the number of deaths was low, this difference is
most likely to be due to chance, although we cannot rule out a
potential and transient increased risk in mortality.
These ﬁndings have a number of important implications.
Firstly, they lend support to the idea that there are a
minimum number of episodes that an individual must
experience before effective immunity is developed against
mild uncomplicated malaria [22,23]. Secondly, it appears that
children who start building immunity after the age of 1 y do
so at a slower rate than those who start in infancy, explaining
the long duration of the rebound. This difference may, in
part, be a reﬂection of the decreasing EIR in the area.
However, it is unlikely to be the main factor involved, as it
would imply a rapid change in the transmission intensity that
would have been reﬂected by a rapid drop in the malaria
incidence in children receiving placebo—and this did not
occur.
Thirdly, the results could be interpreted as suggesting that
the beneﬁts of chemoprophylaxis in infancy may be negated
by the overall slight increase in the number of malaria
episodes in the early years of life. The end of chemo-
prophylaxis was followed by an immediate increase in the
incidence of febrile malaria, well beyond the incidence in
placebo recipients—a so-called rebound effect. This in-
creased risk continued for at least 18 mo and was large
enough that, by the age of 2 y, the cohorts had experienced a
similar number of febrile malaria episodes. Some authors
have speculated that shifting the age pattern of disease to the
right, in other words delaying the acquisition of immunity to
older ages, may pose further hazards by increasing the more
severe consequences of P. falciparum [24,25]. Our data do not
support this conclusion, but instead suggest that a delayed
acquisition of immunity may lead to a small, but not
signiﬁcant, increase in the cumulative number of malaria
episodes and, importantly, to a lower CR of severe malaria. A
similar pattern was observed for severe anaemia, which is the
Table 1. Incidence of Clinical Manifestation of Malaria by Follow-Up Period
Follow-Up Period Symptoms Manifested Placebo Group Chemoprophylaxis Group
Episodes PYAR Incidence Episodes PYAR Incidence
During chemoprophylaxis Clinical malaria 147 153.0 0.96 52 165.2 0.31
Severe malaria 51 159.7 0.32 10 168.0 0.06
Severe anaemia 119 155.2 0.77 47 165.4 0.28
After chemoprophylaxis Clinical malaria 336 469.1 0.72 469 472.1 0.99
Severe malaria 47 490.5 0.10 74 500.9 0.15
Severe anaemia 72 488.5 0.15 117 497.9 0.24
doi:10.1371/journal.pmed.0040242.t001
PLoS Medicine | www.plosmedicine.org July 2007 | Volume 4 | Issue 7 | e2421265
Age and Acquired Immunity to P. falciparum
other major life-threatening complication of malaria in
young children. In summary, shifting the age pattern of
disease to older age groups does not markedly affect the
overall number of mild uncomplicated febrile episodes or
lead to an increase in severe malaria, and it is associated with
an overall decreased CR of severe anaemia.
Finally, the data provide insight into the effects of age on
the clinical manifestations of infection. The observed
reduction in the CR of severe anaemia in the intervention
group provides a strong indication that malarial anaemia is
dependent on the age at which infection takes place: children
aged less than 1 y had a higher rate of anaemia than older
children, as described by previous research [5]. Furthermore,
it appears that this rate is not solely a function of acquired
immunity or level of endemicity, but must be related to an
age-dependent pathophysiological mechanism. Similarly, the
CR of severe malaria was slightly lower in those children who
had been previously chemosuppressed. Our data indicate that
the risk of progressing from a mild to a severe episode of
malaria or anaemia is greater in infants than in older
children—a ﬁnding that has not been documented previ-
ously. Thus, delaying immunity acquisition does not appear
to translate into increases in disease severity.
These results show that reducing exposure early in life in a
very major way, such as through continuous prophylaxis, can
slow down the development of clinical immunity and can lead
to a rebound in the risk of disease. However, shifting the age
pattern of disease may lead to an overall slightly increased
cumulative rate of uncomplicated malaria which was not
associated with an increase in severe malaria or severe
anaemia. The rebound induced by continuous prophylaxis
at this early age has not been documented in other exposure-
reduction interventions such as insecticide-treated bednets or
when administering two or three treatment doses of anti-
malarials at routine immunization contacts during the ﬁrst
year of life (intermittent preventive treatment of malaria in
infants) [26]. Finally, the results point at the intrinsic effect of
young age in determining the risk of severe anaemia and of
severe malaria and the need to target interventions that
prevent malaria in young children and, particularly, in infants.
Supporting Information
Protocol S1. Details of the Statistical Models Used in the Study
Found at doi:10.1371/journal.pmed.0040242.sd001 (85 KB DOC).
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Editors’ Summary
Background. Malaria is a life-threatening disease caused by Plasmodium
falciparum, a parasite that is transmitted from person to person by
infected mosquitoes. People living in areas where malaria is common
(malaria-endemic regions) gradually acquire immunity to this parasite
through repeated exposure to it, but the development of this immunity
is complex. As with other infectious diseases, the immune system has to
learn how to recognize and attack the parasite so that parasitaemia (the
number of parasites in the blood) is kept to a minimum. In addition,
because several symptoms of clinical malaria (for example, the
characteristic fever) are side effects of the immune system’s response
to the parasite, it also has to learn not to overreact to this foreign
invader. Consequently, in malaria-endemic areas, where individuals first
become infected with P. falciparum as infants, many children develop
severe malaria and anemia (parasite-induced killing of red blood cells)
during their first 5 y of life. Later, as their immunity to P. falciparum
develops, they experience less severe disease and reduced parasitaemia.
Why Was This Study Done? Little is known about how quickly
immunity to P. falciparum is acquired or how age affects this process.
This study was done to document the long-term effects of malaria
prophylaxis given to young Tanzanian infants. More specifically, the
researchers examined whether and how prophylaxis affects the rate of
acquisition of malaria immunity, and whether a possible delay in
immunity would be associated with more severe forms of malaria in
children.
What Did the Researchers Do and Find? Infants in Ifakara, a town in
Tanzania, received either antimalarial tablets or placebo (inactive) tablets
every week between the ages of 2 and 12 mo. Cases of clinical malaria
(parasitaemia and fever), severe malaria (parasitaemia plus dehydration,
breathing problems, impaired consciousness, or low blood sugar), and
anemia among the children were recorded until they were 4 y old.
During their first year, the children receiving antimalarial drugs had fewer
episodes of malaria, severe malaria, and anemia than the children
receiving the placebo. After the antimalarial drugs were stopped, cases
of clinical malaria, severe malaria, and anemia were more frequent
among the treated children than among the control children for the next
2 y. By the time they were 4 y old, the treated children had had slightly
more episodes of clinical malaria in total than the control children, but
slightly fewer episodes of severe malaria and anemia.
What Do These Findings Mean? These findings show that reducing
exposure to P. falciparum in early life with continuous malaria
prophylaxis delays the acquisition of immunity to the parasite. They
also show that infants acquire this immunity slightly faster than do older
children, but that this speedier acquisition of immunity is accompanied
by a slightly increased risk of severe malaria and anemia. Because these
findings may, in part, reflect a local decrease in malaria transmission that
occurred during the study, they need confirming in other settings and
with many more children. Nevertheless, they suggest that although age
at first exposure to P. falciparum helps to determine both the rate at
which immunity is acquired and the severity of disease caused by the
parasite, delaying the acquisition of immunity through early prophylaxis
is unlikely to have long-term negative health effects. This information will
help public-health experts to plan prophylactic interventions designed to
control malaria transmission in endemic regions.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040242.
 US Centers for Disease Control and Prevention information on malaria
and on immune responses to malaria (in English and Spanish)
 MedlinePlus encyclopedia page on malaria (in English and Spanish)
 Information from the World Health Organization on malaria (in English,
Spanish, French, Russian, Arabic, and Chinese)
 Short articles from the Wellcome Trust on immunity to malaria and on
malaria and the human immune system
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